⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5104082 | 0.69 | PARP1 (0.33) | — | |
| SCHEMBL38651004 | 0.64 | — | — | |
| SCHEMBL3904647 | 0.63 | — | — | |
| SCHEMBL623667 | 0.60 | — | — | |
| SCHEMBL6827290 | 0.58 | — | — | |
| SCHEMBL4706343 | 0.55 | — | — | |
| SCHEMBL767196 | 0.47 | — | — | |
| SCHEMBL12219421 | 0.45 | CCR8 (0.50) | — | |
| SCHEMBL901147 | 0.32 | — | — | |
| Methane SCHEMBL23044967 | 0.22 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118284601-A | Pyrrolidine derivatives as DDR inhibitors | 奇斯药制品公司 | 2024-07-02 | — | — | CN | disclosed |
| WO-2024129634-A1 | RBM39 SULFONAMIDE INHIBITORS | RECURSION PHARMACEUTICALS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024121130-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA A/S (DK) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024121129-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA A/S (DK) | 2024-06-13 | — | — | WO | disclosed |
| US-20240174710-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR SYNTHESIS | WAVE LIFE SCIENCES LTD. (SG) | 2024-05-30 | — | — | US | disclosed |
| CN-112334454-B | Environment-friendly olefin hydration reaction | 佐治亚州立大学研究基金会公司 | 2024-04-30 | — | — | CN | disclosed |
| US-20240092770-A1 | Heterocycle RMB39 Modulators | RECURSION PHARMACEUTICALS, INC. | 2024-03-21 | — | — | US | disclosed |
| WO-2024039689-A1 | HETEROCYCLE RBM39 MODULATORS | RECURSION PHARMACEUTICALS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| US-20240051966-A1 | CD16A BINDING AGENTS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. | 2024-02-15 | — | — | US | disclosed |
| WO-2024017877-A1 | HETEROARYL DERIVATIVES AS DDRs INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-01-25 | — | — | WO | disclosed |
| US-20130267563-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-20130172292-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-04 | — | — | US | disclosed |
| EP-2603214-A1 | HETEROARYLS AND USES THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2013-06-19 | — | — | EP | disclosed |
| EP-2603216-A1 | HETEROARYLS AND USES THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20120178723-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120172345-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120142732-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| WO-2012021696-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | WO | disclosed |
| WO-2012021615-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | WO | disclosed |
| WO-2012021611-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | WO | disclosed |